Innovation and patient safety have always been the cornerstones of the pharmaceutical industry. Today, much of this innovation comes in the form of complex drug formulations and smarter aseptic manufacturing solutions, alongside evolving regulatory requirements.
These trends create an urgent need for operational agility and enhanced quality—particularly in protecting medication integrity and minimizing contamination risks.
Pharmaceutical companies and CDMOs face the challenge of balancing compliance, flexibility, and efficiency, making Ready-to-Use (RTU) drug containment solutions a strategic enabler to simplify processes while ensuring sterility and regulatory alignment.
Why RTU Matters
Although traditional bulk filling processes are associated with lower expenses for primary packaging, they pose challenges that need to be analyzed. They require separate setups and cleanrooms for vials, prefilled syringes (PFS), and cartridges — driving up initial investment, operating costs, cleanroom footprint, and limiting flexibility. Additionally, extensive glass-to-glass contact also contributes to higher non-quality costs.
By switching from traditional bulk drug containment solutions to sterile drug containment solutions, such as ready-to-use vials, the total cost of ownership (TCO) can be significantly reduced.
By adopting RTU vials, manufacturers can eliminate critical steps such as washing and depyrogenation, automate processes, and reduce human intervention—significantly minimizing potential contamination risks. This approach streamlines operations, enhances efficiency, and allows companies to focus on key activities with the most added value.
Regulatory Drivers: EU GMP Annex 1
The sterile drug product market is projected to grow at a 15% CAGR between 2022 and 2027, driven by rising demand for contamination control and stricter sterility standards. Most notably, the revised EU GMP Annex 1 reflects these growing demands.
Effective August 25, 2023, it introduces stricter guidelines for sterile drug manufacturing. Key principles include:
- Pharmaceutical Quality System (PQS)
- Quality Risk Management (QRM)
- Contamination Control Strategy (CCS)
These aim to ensure sterility, manage risks, and control contamination, especially during aseptic processing. Manufacturers must provide robust documentation to demonstrate compliance. Any actions and changes may require significant economic investments and/or could lead to interruptions in production. Facilities and equipment may need upgrades, such as RABS or isolators, to minimize human contact and contamination risks.
RTU packaging offers a practical solution to meet these requirements while reducing costs and complexity.
These are some examples of the benefits that industry players can obtain from the use of sterile containers:
- Reduced contamination risks and production errors
- Increased efficiency and lower non-quality costs
- Full integration with QRM principles (ICH Q9 & Q10)
- Compliance with evolving regulatory standards
- Enhanced sterility assurance and process validation
EZ-fill® Platform: A Proven Solution
At Stevanato Group, we offer RTU solutions, allowing pharmaceutical companies and contract manufacturers to outsource production processes, reduce unnecessary revamping costs, and concentrate internal resources on key activities.
Our EZ-fill® is a fully integrated containment solution comprising pre-sterilized vials, cartridges, and syringes for your aseptic manufacturing, meeting the strictest requirements for contamination control.
Why choose our RTU vial solutions?
- Sterility Assurance: Pre-washed and pre-sterilized to minimize contamination risks.
- Efficiency: Streamline production processes and reduce downtime.
- Quality: Protect the sensitive nature of biologics, maintaining stability and efficacy.
Supply Chain Security: with established manufacturing capacity in Italy, and new operations for RTU vials expected to start early next year also in Fishers, IN, U.S., we’re mitigating supply chain risks while ensuring consistent access to premium drug containment solutions – helping ensure reliable access to high-quality containment solutions for biologics manufacturing.
As regulatory frameworks tighten and biologics demand grows, RTU vials - like EZ-fill® solutions - enable pharma companies and CDMOs to achieve compliance, efficiency, and patient safety—while focusing on innovation and value creation. Learn more: EZ-fill® RTU Vials | Sterile Vials for Injection